1800 519 711 | ltrpharma.com | [email protected] LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Clinical and Commercial Update: Investor Webinar 2 October 2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to invite its shareholders and other...
Clinical and Commercial Update - Investor Webinar
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from LTR Pharma
- SPONTAN Phase II Final Results
- Notice of Annual General Meeting/Proxy Form
- Application for quotation of securities - LTP
- Investor Presentation
- LTR Expands Men's Health Portfolio with KYZATREX Pilot
Later from LTR Pharma
- First ROXUS Prescriptions Fulfilled in the United States
- Investor Webinar Presentation
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- SPONTAN passes 2,000 dispensed units in Australia
- SPONTAN to be Evaluated in Pulmonary Arterial Hypertension
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma